Publications by authors named "Laina D Mercer"

Claim this Profile
S
Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trial.
Laina D Mercer, Arlene C Seña, E Ross Colgate, Jessica W Crothers, Peter F Wright

Lancet Infect Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and non-inferiority of multidose and single-dose vial formulations of EuTCV Vi-CRM197 versus Typbar TCV in healthy participants in Kenya and Senegal: a multicentre, observer-blind, randomised, phase 3 study.
Birahim Pierre Ndiaye, Lucy Koech, Laina D Mercer, John J Aponte, Badara Cisse

Lancet Glob Health· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study.
Robert W Frenck, Abdi Naficy, Jodi Feser, Michelle P Dickey, Victor H Leyva-Grado, Laina D Mercer

Lancet· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One year follow up of phase 1/2 randomized, placebo controlled trial of NDV-HXP-S vaccine in Thailand.
Weerapong Phumratanaprapin, Viravarn Luvira, Saranath Lawpoolsri, Juthaporn Cowan, Sant Muangnoicharoen, Laina D Mercer

NPJ Vaccines· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum-Exposed, Drug-Treated Kenyan Adults.
Nathanial K Copeland, Lucas Otieno, June Doryne Otieno, Solomon Otieno, Salome Chira, Laina D Mercer

J Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of an Escherichia coli-produced bivalent human papillomavirus vaccine (Cecolin) in girls aged 9-14 years in Ghana and Bangladesh: a randomised, controlled, open-label, non-inferiority, phase 3 trial.
Tsiri Agbenyega, Anne E Schuind, Samuel Adjei, Kalpana Antony, John J Aponte, Laina D Mercer

Lancet Infect Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S).
Viravarn Luvira, Saranath Lawpoolsri, Weerapong Phumratanaprapin, Anan Jongkaewwattana, Sira Nanthapisal, Laina D Mercer

Vaccine· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil.
Érique José Farias Peixoto de Miranda, Rodrigo T Calado, Fernanda Castro Boulos, José Alfredo de Sousa Moreira, Fabiane Fernandes Machado, Laina D Mercer

Vaccine· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.
Vu Dinh Thiem, Dang Duc Anh, Vu Hai Ha, Nguyen Van Thom, Tran Cong Thang, Laina D Mercer

Vaccine· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of RTS,S/AS01 vaccine-induced humoral biomarkers predictive of protection against controlled human malaria infection.
Rachel L Spreng, Kelly E Seaton, Lin Lin, Sir'Tauria Hilliard, Gillian Q Horn, Laina D Mercer

JCI Insight· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genotypic analysis of RTS,S/AS01 malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5-17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial.
Michal Juraska, Angela M Early, Li Li, Stephen F Schaffner, Marc Lievens, Laina D Mercer

Lancet Infect Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Socioeconomic, Demographic, and Environmental Factors May Inform Malaria Intervention Prioritization in Urban Nigeria.
Chilochibi Chiziba, Laina D Mercer, Ousmane Diallo, Amelia Bertozzi-Villa, Daniel J Weiss

Int J Environ Res Public Health· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacy.
Michal Juraska, Angela M Early, Li Li, Stephen F Schaffner, Marc Lievens, Laina D Mercer

medRxiv· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study.
Rahsan Erdem, Ilse De Coster, Kanchanamala Withanage, Laina D Mercer, Arnaud Marchant

Vaccine· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Introducing ROTAVAC® to the occupied Palestinian Territories: Impact on diarrhea incidence, rotavirus prevalence and genotype composition.
Wolfgang Rennert, Musa Hindiyeh, Majd Allahham, Laina D Mercer, Khalil I Hamad

Vaccine· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials.
Rahnuma Wahid, Laina D Mercer, Tirza De Leon, Rodrigo DeAntonio, Xavier Sáez-Llorens

Lancet Microbe· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
Anh Duc Dang, Thiem Dinh Vu, Ha Hai Vu, Van Thanh Ta, Anh Thi Van Pham, Laina D Mercer

Vaccine· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021.
Javier Martin, Cara C Burns, Jaume Jorba, Lester M Shulman, Andrew Macadam, Laina D Mercer

MMWR Morb Mortal Wkly Rep· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Impact of Programmatic Mass Drug Administration for Malaria in Zambia Using Routine Incidence Data.
Maya Fraser, John M Miller, Kafula Silumbe, Michael Hainsworth, Mutinta Mudenda, Laina D Mercer

J Infect Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.
Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, Sant Muangnoicharoen, Supitcha Kamolratanakul, Laina D Mercer

EClinicalMedicine· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2a randomized, single-center, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of oral iOWH032 against cholera diarrhea in a controlled human infection model.
Rahsan Erdem, Gwen Ambler, Mohamed Al-Ibrahim, Katarzyna Fraczek, Steven D Dong, Laina D Mercer

PLoS Negl Trop Dis· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial.
Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, Sant Muangnoicharoen, Supitcha Kamolratanakul, Laina D Mercer

medRxiv· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Micronutrient and Environmental Enteric Dysfunction Assessment Tool and evaluation of biomarker risk factors for growth faltering and vaccine failure in young Malian children.
Michael B Arndt, Jason L Cantera, Laina D Mercer, Michael Kalnoky, Heather N White

PLoS Negl Trop Dis· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of state weights on national vaccination coverage estimates from household surveys in Nigeria.
Tracy Qi Dong, Dale A Rhoda, Laina D Mercer

Vaccine· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the positive association between middle-income and rich household wealth and adult sub-Saharan African women's overweight status modified by the level of education attainment? A cross-sectional study of 22 countries.
Ifeoma D Ozodiegwu, Henry V Doctor, Megan Quinn, Laina D Mercer, Ogbebor Enaholo Omoike

BMC Public Health· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis